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2  Abbreviations
A2M α
2
-macroglobulin
ACT α
1
-antichymotrypsin
ANN artificial neural network
API α
1
-protease inhibitor
AUC area under the curve
BPH benign prostatic hyperplasia
CI confidence interval
DRE digital rectal examination
hK2 human kallikrein 2
IGF-I insulin-like growth factor I
IGFBP-3 insulin-like growth factor binding protein 3
LVQ learning vector quantization
MLP multilayer perceptron
PSA prostate-specific antigen
ROC receiver-operating characteristic
SD standard deviation
TRUS transrectal ultrasound
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3  Introduction
Screening for prostate cancer by measuring
the serum concentration of prostate-specific
antigen (PSA) is recommended health
policy in the USA. Final scientific evidence
that prostate cancer screening reduces mor-
tality in prostate cancer is still lacking.
Ongoing randomized screening trials will
hopefully reveal whether screening is ben-
eficial. The prostate cancers detected by PSA
screening have been shown to mostly be
clinically relevant and confined to the pros-
tate gland, and thus potentially curable by
radical treatment. A major problem of us-
ing serum PSA for screening is the high fre-
quency (about 70%) of false positive test
results caused mainly by benign prostatic
hyperplasia (BPH) but also by prostatic in-
flammation and other prostatic diseases.
This causes expenses for the society and
unnecessary anxiety for the men with falsely
elevated serum PSA concentrations. Several
methods for reducing the number of false
positive PSA results have been developed.
Of these, the proportion of free PSA has been
most promising and by using this method
20–30% of the false positive PSA results
can be identified. However, a larger reduc-
tion of the number of false positive PSA
results is desirable.
This study was undertaken to evaluate
existing methods and to develop new and
better ones for reduction of the number of
false positive test results in PSA based
screening for prostate cancer.
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4  Review of the literature
4.1 Epidemiology of prostate cancer
4.1.1 Incidence and prevalence
Adenocarcinoma of the prostate is the most
commonly diagnosed cancer among men in
industrialized countries, when basal cell
cancer is excluded (Parkin, et al., 1997). In
Finland 2 839 men were diagnosed with
prostate cancer in 1997. The age standard-
ized incidence rate was 72 new cases per
100 000 inhabitants (Finnish Cancer Reg-
istry, 2000), and it has been steadily increas-
ing during the past 30 years: on average the
yearly numbers were 28, 36, and 48 cases
per 100 000 inhabitants in 1970–1974,
1980–1984, and 1990–1994, respectively
(Finnish Cancer Registry, 2000). Mean age
at diagnosis was 73 years in 1985–1994,
and prostate cancer is rarely diagnosed in
men younger than 45 years of age (Finnish
Cancer Registry, 2000). The incidence of
prostate cancer in 1990 was highest in
Northern America, Australia, New Zealand,
the Carribean, and Western Europe (Tab-
le 1) (Ferlay, et al., 1998, Parkin, et al.,
1999). The incidence is higher among Af-
rican-American than among white men
(Hankey, et al., 1999). The lowest incidence
rates in 1990 were seen in Asia and North-
ern Africa (Ferlay, et al., 1998, Hsing, et
al., 2000). When PSA screening was intro-
duced the incidence in the United States
initially increased rapidly during 1988–
1992 because a pool of men with latent pros-
tate cancer was diagnosed. Since 1993 the
incidence has been decreasing but it remains
higher than before the PSA era (Fremgen,
et al., 1999, Hankey, et al., 1999). In Fin-
land the incidence was still increasing in
1997 (Finnish Cancer Registry, 2000).
Autopsy studies have shown that about
half of 50-year old men and 70–90% of men
older than 80 years have latent prostate can-
cer, discovered only on postmortem exami-
nation (Franks, 1954, Sakr, et al., 1993,
Sakr, et al., 1994). However, the life time
risk of being diagnosed with prostate can-
cer is 9–11% (Scardino, 1989, Stamey, et
al., 1993, Merrill, et al., 1997).
Region
Eastern Africa
Middle Africa
Northern Africa
Southern Africa
Western Africa
Carribean
Central America
South America
Northern America
Eastern Asia
South-Eastern Asia
South Central Asia
Western Asia
Eastern Europe
Northern Europe
Southern Europe
Western Europe
Australia/New Zealand
World
More developed regions
Less developed regions
*Age standardized rate (World population) per 100 000
inhabitants
Incidence rate*
16.8
29.6
5.1
31.0
23.9
42.4
24.8
26.8
92.4
2.4
5.9
4.5
7.1
14.1
34.7
16.9
39.6
49.7
19.8
40.1
7.6
Mortality rate*
9.3
17.8
3.1
18.7
14.4
22.1
13.2
15.9
18.5
1.3
3.5
2.8
4.2
8.4
18.6
13.2
19.7
18.2
8.3
14.3
4.5
Table 1. Estimated age standardized incidence and
mortality rates of prostate cancer in 1990 in various
regions of the world (Ferlay 1998 and Parkin 1999).
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4.1.2 Mortality
The age standardized mortality rate of pros-
tate cancer in 1990 was 18–19 deaths per
100 000 inhabitants in 1990 in Northern
Europe and Northern America, whereas it
was only 1.3 in Eastern Asia (Table 1)
(Ferlay, et al., 1998). According to the SEER
(Surveillance, Epidemiology, and End Re-
sults) database, the prostate cancer mortal-
ity rates in the United States increased 3%
in 1987–1991 and decreased 5% in 1992–
1997 (Ries, et al., 2000). The mortality rates
have correlated with the rising and falling
incidence rates caused by screening with
PSA (Hankey, et al., 1999). It has been sug-
gested that this correlation is due to attri-
bution bias, i.e., recently diagnosed patients
who die of other causes are mislabeled as
dying of prostate cancer (Feuer, et al., 1999).
4.1.3 Prognosis
In Finland the survival rates have been im-
proving and the 5-year relative survival rate
was 64% in 1985–1994, as compared to
57% in 1975–1984 (Dickman, et al., 1999).
In 1990 the estimated 5-year survival in the
whole world was 58%. In Northern
America the average 5-year survival was the
highest (79%) and in Southern Europe the
lowest (22%) (Parkin, et al., 1999). The
survival rates of prostate cancer are mainly
affected by the stage of the disease at diag-
nosis (Table 2) (Schröder, et al., 1992,
Vaughan, et al., 1998), and the stage dis-
tribution is affected by how early and in
what way the prostate cancer is diagnosed.
The high 5-year survival rate in the USA is
associated with stage migration, i.e., pros-
tate cancer is increasingly detected at early
stages due to screening with PSA (Smith,
et al., 1997). In Finland the 5-year survival
rate in 1985–1994 of patients with local-
ized prostate cancer, regional metastases,
and distant metastases was 84%, 65%, and
25%, respectively. The 10-year survival rate
for patients with localized prostate cancer
was 64%, while it was 9% for those with
distant disease and 45% for all cases pooled
together (Dickman, et al., 1999). In north-
ern Sweden the 10-year survival rate of pa-
tients diagnosed with prostate cancer in
1971–1987 was 45% (Grönberg, et al.,
1994), and it tended to be lower (39%) for
men younger than 55 years but the differ-
ence was not significant.
Review of the literature
TX
TO
T1
T1a
T1b
T1c
T2
T2a
T2b
T2c
T3
T3a
T3b
T3c
T4
T4a
T4b
NX
NO
N1
N2
N3
MX
M0
M1
M1a
M1b
M1c
Primary tumor cannot be assessed
No evidence of primary tumor
Clinically unapparent tumor–not palpable or
visible by imaging
Tumor found incidentally in tissue removed at
transurethral resection: 5% or less of tissue is
cancerous
Tumor found incidentally at transurethral
resection: More than 5% of tissue is cancerous
Tumor found by prostate biopsy because of
PSA elevation
Palpable tumor confined within the prostate
Tumor involves half of a lobe or less
Tumor involves more than half of a lobe
Tumor involves both lobes
Palpable tumor extending through prostate
capsule and/or involving seminal vesicle(s)
Unilateral extracapsular extension
Bilateral extracapsular extension
Tumor invades seminal vesicle(s)
Tumor is fixed or invades adjacent structures
other than seminal vesicles
Tumor invades bladder neck and/or external
sphincter and/or rectum
Tumor invades levator muscles and/or is fixed
to pelvic wall
Regional lymph nodes cannot be assessed
No regional lymph node metastases
Metastasis in a single regional lymph node, < 2
cm in greatest dimension
Metastasis in a single regional lymph node, ≥ 2
cm but not ≥ 5 cm in greatest dimension, or
multiple regional lymph nodes, none ≥ 5 cm in
greatest dimension
Metastasis in a regional lymph node ≥ 5 cm in
greatest dimension
Presence of distant metastases cannot be
assessed
No distant metastases
Distant metastases
Involvement of nonregional lymph nodes
Involvement of bones
Involvement of other distant sites
Table 2. The TNM system for staging of prostate cancer
(Schröder, et al., 1992, Vaughan, et al., 1998).
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4.2 Risk factors for prostate cancer
Obesity and a diet rich in fat have been
shown to increase prostate cancer risk in
some studies (Whittemore, et al., 1995,
Giles and Ireland, 1997, Lee, et al., 1998),
but a prospective study in Norway showed
no correlation between fat intake and pros-
tate cancer risk (Veierod, et al., 1997). The
possible correlation may be due to increased
levels of testosterone (Shaneyfelt, et al.,
2000), or free testosterone in serum
(Demark-Wahnefried, et al., 1997), but
other studies have shown that prostate can-
cer risk is not affected by serum testoster-
one or estrogen (Vatten, et al., 1997,
Heikkilä, et al., 1999). Tobacco smoking
increases both the risk of being diagnosed
with and the risk of dying of prostate can-
cer (Hsing, et al., 1990, Coughlin, et al.,
1996). However, other studies indicate that
there is no causal link between tobacco
smoking and occurrence of prostate cancer
(Adami, et al., 1996, Andersson, et al.,
1996). Alcohol has not been shown to play
a role in development of prostate cancer
(Adami, et al., 1992, Andersson, et al.,
1996). Supplementation with ß-carotene
increases morbidity and mortality of pros-
tate cancer, whereas alpha-tocopherol and
Vitamin E have the opposite effect
(Heinonen, et al., 1998).
4.3 Diagnosis of prostate cancer
4.3.1 Symptoms and differential diagnosis
Prostate cancer can be suspected on the
basis of clinical symptoms such as reduced
urinary flow, urinary retention, hematuria,
urinary tract infection, blood in semen, or
back pain due to bone metastases (Lukkari-
nen, et al., 1999). However, these symp-
toms are neither very specific nor sensitive
for prostate cancer, and especially among
men with local prostate cancer symptoms
are rare. Furthermore, urinary tract symp-
toms are mostly caused by BPH, which is
the most common prostatic disease in men.
The incidence of BPH increases with age
(Berry, et al., 1984), and about 80% of men
older than 60 years have histological BPH
while 40% have symptoms (Garraway, et
al., 1991).
4.3.2 Digital rectal examination and
transrectal ultrasound
By digital rectal examination (DRE) the size
and shape of the prostate can be estimated.
Indurations, irregularities and nodes are
associated with prostate cancer but are not
specific. Small tumors are mostly impossible
to detect by DRE. The positive predictive
value of DRE is low (4–35%) in men with
serum concentrations of prostate-specific
antigen (PSA) below 4 µg/L because of the
low prevalence of prostate cancer in this
group of men (Schröder, et al., 1998, Schrö-
der, et al., 2000). However, among men
with a PSA of 4 to 10 µg/L detection of
organ confined prostate cancer can be im-
proved by using DRE together with serum
PSA (Catalona, et al., 1994a, Bangma, et
al., 1995a). By transrectal ultrasound
(TRUS) it is possible to get a much more
precise estimate of prostate volume (Wata-
nabe, et al., 1975, Terris and Stamey, 1991,
Rietbergen, et al., 1998), and to visualize
the various zones and the echogenic struc-
ture of the prostate (Babaian, et al., 1992a).
Prostate cancer is usually seen as a hypo-
echoic area, and this has been used in some
studies to predict the outcome of prostate
biopsies (Watanabe, et al., 1980, Kranse,
et al., 1999). Both DRE and TRUS are in-
vestigator-dependent and require much
practice to master.
4.3.3 Prostate-specific antigen
PSA is a serine protease with 237 amino
acids (Lilja, 1985, Watt, et al., 1986,
Lundwall and Lilja, 1987, Schaller, et al.,
1987), which was first isolated from pros-
tate tissue and characterized in 1979
Review of the literature
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(Wang, et al., 1979). It is synthesized in
prostatic epithelial cells as a preprotein
(preproPSA) with 261 amino acids and con-
verted to the zymogen form (proPSA) com-
prising 244 amino acids during synthesis
(Lundwall and Lilja, 1987). ProPSA is ap-
parently cleaved (and thus activated) when
secreted into semen, because no proPSA is
found in seminal fluid (Watt, et al., 1986,
Schaller, et al., 1987). In semen PSA may
be further degraded to ‘nicked’ forms, in
which the peptide chain is cut or nicked at
1 to 3 points (Watt, et al., 1986, Chris-
tensson, et al., 1990, Zhang, et al., 1995).
In seminal fluid PSA exists in five isoforms
A–E, of which A and B are intact and en-
zymatically active (Zhang, et al., 1995).
The physiological role of PSA is to digest
the gel-forming proteins causing liquefac-
tion of the semen (Lilja, 1985, Lilja, et al.,
1987). The concentration of PSA in semen
is 0.5–2 mg/L which is about one million-
fold the normal concentration in serum.
PSA is organ-specific and expressed both
in normal and malignant prostatic epithe-
lial cells. Low expression has been found in
other tissues (Kamoshida and Tsutsumi,
1990, Diamandis and Yu, 1997). Female
breast tissue has been shown to be the most
notable source of nonprostatic PSA, but the
concentration of PSA in seminal plasma is
1 000-fold that in nipple aspirate and
10 000-fold that in breast milk (Diamandis
and Yu, 1997). The serum concentration
of PSA is elevated in men with prostate
cancer although the PSA expression in
malignant prostatic epithelial cells has been
shown to be somewhat lower than in nor-
mal cells (Abrahamsson, et al., 1988). To
reach circulation from benign prostatic tis-
sue PSA has to diffuse through the ductal
walls or from the epithelial cells into ex-
tracellular fluid. Thus only a very small
proportion of the PSA produced reaches
serum. In prostate cancer the ductal struc-
ture of the prostate is deranged and it has
been suggested that PSA can be actively
secreted into extracellular fluid and the cap-
illaries of the tumor (Stenman, et al., 1999).
Because of this the contribution of pros-
tate cancer tissue to the serum concentra-
tion of PSA is 10-fold that of BPH tissue
and 30-fold that of normal prostatic tissue
(Stamey, et al., 1987).
Elevation of the serum PSA concentra-
tion is not specific to prostate cancer: el-
evated levels may also be caused by BPH
and other benign prostatic diseases such as
prostatitis (Brawer, 1999). In fact, about
65–75% of the men with an elevated se-
rum PSA above the generally used cutoff
value 4 µg/L do not have prostate cancer in
biopsy (Table 3) (Catalona, et al., 1991,
Brawer, et al., 1992, Labrie, et al., 1992,
Catalona, et al., 1993, Labrie, et al., 1993,
Catalona, et al., 1994a, Schröder, et al.,
1998, Määttänen, et al., 1999). The num-
ber of false positive PSA results can be re-
duced by using higher cutoff values, but
then the sensitivity will decrease as a con-
siderable number of cancer cases are missed
while an increasing proportion of the cases
found are no more at a curable stage.
4.3.4 Histological diagnosis
When prostate cancer is suspected the di-
agnosis is confirmed by histopathological
examination of tissue samples obtained by
needle biopsies. Routinely, 6–8 needle bi-
opsies are taken under TRUS guidance.
Additional biopsies are often taken if sus-
picious areas are identified by TRUS or
DRE. The sensitivity of first round sextant
prostate biopsies for prostate cancer is not
perfect and 10–30% of repeat biopsies taken
from men with one previous negative set of
sextant biopsies will be positive (Fleshner,
et al., 1997, Borboroglu, et al., 2000,
Djavan, et al., 2000). WHO grade and
Gleason score (Table 4) describe the degree
of differentiation of the tumor (Mostofi,
1975, Gleason, 1992). Poorly differentiated
tumors are associated with more aggressive
growth and larger risk of extraprostatic
spread (Albertsen, et al., 1998).
Review of the literature
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4.4 Treatment of prostate cancer and
complications of the treatment
4.4.1 Local prostate cancer
If the prostate cancer is localized to the pros-
tate gland it can be treated by surgery (Cata-
lona, et al., 1999), radiotherapy (Shipley,
et al., 1999), brachytherapy (Blasko, et al.,
1996), and sometimes only actively fol-
lowed (watchful waiting) (Johansson, et al.,
1992, Catalona, 1994b). The aim of radi-
cal prostatectomy is to remove the cancer
tissue entirely, which is mostly achievable
when the tumor is confined to the prostate
(stage T1–T2N0M0). Due to the risk of
complications, radical prostatectomy is usu-
ally performed only when the expected life
time of the patient is at least ten years. An
alternative to surgery is radical radio-
therapy, which may be curative also when
the cancer has spread locally outside the
prostatic capsule (T1–T3N0M0) (Catalona,
1994b, Lukkarinen, et al., 1999). Radio-
therapy can also be given interstitially
(brachytherapy) by implanting radioactive
beads in the prostate (Blasko, et al., 1996).
For patients older than 70 years with a clini-
cally localized (T1–T2N0M0) and well-dif-
ferentiated (Gleason score 2–4) prostate
cancer watchful waiting, i.e., follow-up by
clinical and laboratory methods every sixth
month is a viable alternative. Randomized
studies comparing various treatment modes
for local prostate cancer are still lacking. A
non-randomized study in one hospital
showed that the 5-year probability of free-
dom from PSA failure (PSA level increas-
ing after treatment) was comparable after
radical prostatectomy, radiotherapy and
brachytherapy (D'Amico, et al., 1998).
However, brachytherapy was associated
with a lower probability of freedom from
Key: PCa = Number of prostate cancer cases; Bx = Number of biopsied men
Author
Catalona, et al. 
Brawer, et al.
Labrie, et al.
Labrie, et al.
Catalona, et al.
Catalona, et al.
Schröder, et al.
Määttänen, et al.
All
PSA 4–10 µg/L
PCa/Bx (%)
19/85 (22%)
23/87 (26%)
23/89 (26%)
101/716 (14%)
174/652 (27%)
143/548 (26%)
238/988 (24%)
63/327 (19%)
784/3 492 (22%)
PSA ≥ 10 µg/L
PCa/Bx (%)
18/27 (67%)
9/18 (50%)
18/35 (51%)
95/240 (40%)
122/208 (59%)
73/138 (53%)
113/196 (58%)
43/74 (58%)
491/936 (52%)
PSA ≥ 4 µg/L
PCa/Bx (%)
37/112 (33%)
32/105 (30%)
41/124 (33%)
196/956 (21%)
296/860 (34%)
216/686 (31%)
351/1184 (30%)
106/401 (26%)
1 275/4 428 (29%)
Table 3. Proportion of men with prostate cancer on biopsy according to level of serum PSA in various screening
studies.
1991
1992
1992
1993
1993
1994
1998
1999
Year
Review of the literature
1
2
3A
3B
3C
4A
4B
5A
5B
Simple round glands, close-packed in rounded
masses with well-defined edges
Simple rounded glands, loosely packed in
vague, rounded masses with loosely defined
edges
Medium sized single glands of irregular shape
and irregular spacing with ill-defined infiltrating
edges
Very similar to 3A, but small to very small
glands, which must not form significant chains
or cords
Papillary and cribriform epithelium in smooth,
rounded cylinders and masses; no necrosis
Small, medium, or large glands fused into
cords, chains, or ragged, infiltrating masses
Very similar to 4A, but with many large clear
cells, sometimes resembling "hypernephroma"
Papillary and cribriform epithelium in smooth,
rounded masses, more solid than 3C and with
central necrosis
Anaplastic adenocarcinoma in ragged sheets
Grade Description
Table 4. The Gleason grading system of prostate cancer.
Reference (Gleason, 1992)
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PSA failure among high-risk patients (with
a PSA above 10 µg/l and a Gleason score of
7 or higher).
After radical prostatectomy the incidence
of impotence is 30–60% depending on age,
tumor stage, and surgical technique (Cata-
lona, 1994b). Thus, the risk may be reduced
in selected patients by using a nerve-spar-
ing technique (Quinlan, et al., 1991). In-
continence occurs in 5–15% of the patients
(Catalona, 1994b, Walsh, et al., 1994).
Radical radiotherapy also causes complica-
tions: impotence (40–60%), chronic cysti-
tis (8%), urethral stricture (4%), chronic
proctitis (2%), and incontinence (<1%)
(Catalona, 1994b). Brachytherapy has been
associated with a lower frequency of impo-
tence, about 20% (Blasko, et al., 1996).
4.4.2 Advanced prostate cancer
Endocrine therapy is the main treatment of
advanced metastatic prostate cancer (Cata-
lona, 1994b, Lukkarinen, et al., 1999). Well
differentiated prostate cancer cells are de-
pendent on androgens and the aim of endo-
crine manipulations is to deprive the tu-
mor cells of testosterone. This can be
achieved by orchiectomy, administration of
estrogens, antiandrogens or synthetic ago-
nists of gonadotropin-releasing hormone
(GnRH) derivates. Estrogens (polyestradiole
phosphate, stilbestrol) suppress the secre-
tion of pituitary luteinizing hormone (LH),
which in turn leads to reduced testicular
output of testosterone. Synthetic GnRH
analogs act similarly. After an initial tran-
sient increase in LH secretion, long-term
administration of GnRH agonists suppress
LH release, achieving in effect a chemical
castration. Antiandrogens (cyproterone ac-
etate, bicalutamide, flutamide, nilutamide)
block the effect of androgens on prostate
cancer cells, but are not recommended as
the only treatment for prostate cancer (Luk-
karinen, et al., 1999). Antiandrogens are
used in total androgen blockade treatment
as an adjuvant to surgical or chemical cas-
tration, but in randomized trials total
androgene blockade has not provided longer
survival than conventional castration (Pros-
tate Cancer Trialists’ Collaborative Group,
1995, Eisenberger, et al., 1998).
Endocrine treatment based on androgen
deprivation causes impotence, gynecomas-
tia, change of the male habitus, and re-
duced muscle mass (Lukkarinen, et al.,
1999). Estrogen treatment is associated
with cardiovascular side effects, but these
can be reduced by administrating estrogen
parenterally (Hedlund and Henriksson,
2000).
4.5 Screening for prostate cancer with
serum PSA
In most cases serum PSA becomes elevated
5–10 years before clinical diagnosis of pros-
tate cancer (Carter, et al., 1992, Stenman,
et al., 1994, Gann, et al., 1995). Thus, pros-
tate cancer can be detected long before clini-
cal presentation by screening with serum
PSA, and most screen-detected prostate can-
cers are confined to the prostate and can be
removed by radical prostatectomy (Mettlin,
et al., 1997). Population screening by se-
rum PSA has been recommended in order
to reduce mortality and morbidity from
prostate cancer (Smith, et al., 2000), but
screening has not yet been shown to do this
(Adami, et al., 1994, Collins and Barry,
1996). Prospective population-based stud-
ies have been initialized (Auvinen, et al.,
1996), and these will hopefully reveal
whether prostate cancer screening is ben-
eficial.
4.5.1 Validity of the serum PSA test
In ongoing randomized population-based
screening studies serum PSA has been
found to be elevated above 4 µg/L in 8.5–
12.5% of the screened population (Schrö-
der, et al., 1998, Määttänen, et al., 1999).
In 21–34% of men with a serum PSA
>4 µg/L cancer was found on prostate bi-
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opsy (Table 3) (Catalona, et al., 1991,
Brawer, et al., 1992, Labrie, et al., 1992,
Catalona, et al., 1993, Labrie, et al., 1993,
Catalona, et al., 1994a, Schröder, et al.,
1998, Määttänen, et al., 1999). Thus the
frequency of false positive results is 66–
79%. This is a drawback of the PSA test
because false positive results cause consid-
erable emotional stress for the patient and
expenses for the society (Brawer, 1999,
Smith, et al., 2000). However, some of the
initially negative sextant biopsies are false
negatives and at rebiopsy more cancer cases
will be detected (Fleshner, et al., 1997,
Borboroglu, et al., 2000).
Schröder et al. (Schröder, et al., 1998),
took biopsies from part of the patients with
PSA values below 4 µg/L and based on the
detection rates in the low strata of serum
PSA concentrations 7.9% (730 of 9211) of
the men with a serum PSA below 4 µg/L
were estimated to would have had a pros-
tate cancer detected by biopsy. On the ba-
sis of this study it can be calculated that if
all men would be biopsied regardless of the
PSA concentration 35% of the cases with
biopsy detected prostate cancer would have
a serum PSA of 4 µg/L or higher, i.e., the
sensitivity of the PSA test would be 35%.
The specificity would correspondingly be
90%. This is in line with the findings in
two serum bank studies that showed 91–
92% sensitivity and 46–51% specificity of
detecting prostate cancer within 6–10 years
from serum PSA sampling (Stenman, et al.,
1994, Gann, et al., 1995). In prostate can-
cer screening a higher sensitivity of the PSA
test can be achieved by repeated screening
(Carter, et al., 1997a).
The range of serum PSA concentrations
of 4–10 µg/L has been called the diagnos-
tic grey zone because the prostate cancer is
detected in only about 20–25% of the men
with a serum PSA in this range. There is a
need to identify low-risk patients in this
range who could be spared prostate biopsy.
Among patients with a serum PSA of 10–
20 µg/L in screening, about half have pros-
tate cancer at biopsy, and of the cancers de-
tected less than half are pathologically lo-
calized to the prostate and thus radically
treatable (Catalona, et al., 1993).
4.5.2 Clinical relevance of detected cancers
Autopsy studies have shown that more than
50% of men older than 50 years have his-
tological evidence of prostate cancer
(Franks, 1954, Sakr, et al., 1994). Because
only 9–11% are diagnosed with prostate
cancer 80% of these cancers will not de-
velop into clinical disease. In randomized
population-based screening studies prostate
cancer has been detected in 2.1–3.3% of
the screened population when taking pros-
tate biopsies from men with a serum PSA
concentration above 4 µg/L (Schröder, et al.,
1998, Määttänen, et al., 1999). Thus less
than 10% of the latent prostate cancers are
detected by the first round of screening.
Screening appears to detect clinically rel-
evant tumors as more than 95% of the
screen-detected cancers are considered clini-
cally significant in terms of tumor size and
differentiation (Catalona, et al., 1993).
Epstein et al. found that 16% of the pa-
tients with T1c prostate cancer had poten-
tially biologically insignificant tumors
(Epstein, et al., 1994). Hugosson et al. re-
cently showed that the cumulative risk of
having clinical prostate cancer is 33% for
men with a PSA of 3 µg/L or higher
(Hugosson, et al., 2000). However, the true
clinical relevance of the screen-detected
cancers, in terms of mortality and morbid-
ity, remains to be shown in prospective
studies.
4.6 Methods used to improve the
performance of the serum PSA test
A method that improves the accuracy of the
serum PSA test should either reduce the
number of false positive or false negative
PSA results, or both. Several concepts have
been suggested.
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4.6.1 Age-specific reference ranges
Concentrations of serum PSA correlate posi-
tively with prostate volume and age
(Babaian, et al., 1990, Babaian, et al.,
1992b). An increased concentration of se-
rum PSA is mostly caused by BPH, the
prevalence of which rapidly increases after
age 50. Age-specific reference ranges of PSA
have been suggested to compensate for the
increase in PSA attributable to age (Oester-
ling, et al., 1993, Oesterling, et al., 1995),
and to reduce the number of false negative
PSA results in young men and false posi-
tive PSA results in older men. The upper
reference limit calculated on the basis of the
95th percentile of serum PSA among
healthy men has been determined to be 2.5,
3.5, 4.5, and 6.5 µg/L for men aged 40–49,
50–59, 60–69, and 70–79, respectively
(Oesterling, et al., 1995). Use of these ref-
erence limits lowers the detection rate of
prostate cancer in older age groups in which
the prevalence of the disease is highest. Age
specific reference ranges have been criticized
for reducing the detection rate and decreas-
ing the expected survival time of the de-
tected cancer cases (Etzioni, et al., 1996).
Therefore age-specific reference ranges giv-
ing 95% sensitivity of cancer detection have
been proposed (Morgan, et al., 1996). The
proportion of free PSA is not dependent on
age and a cutoff of 15% has been suggested
for all age groups (Oesterling, et al., 1995).
4.6.2 Increase in serum PSA with time (PSA
velocity)
Men who are developing prostate cancer
have a faster increase of the serum PSA con-
centration than other men. An increase of
serum PSA larger than 0.75 µg/L per year
is associated with a significantly increased
risk of developing prostate cancer (Carter,
et al., 1992, Smith and Catalona, 1994).
This method, which is also called PSA ve-
locity, is mainly intended to be used in men
with PSA values below 4 µg/L and can
therefore reduce the number of false nega-
tive PSA results. However, this method is
laborious and slow requiring repeated PSA
measurements during several years. Another
problem is the considerable day-to-day
variation of serum PSA (Ornstein, et al.,
1997). Furthermore, the proportion of free
PSA has been shown to be a more accurate
diagnostic variable than PSA velocity
among men with a serum PSA of 2.5–4.0
µg/L (Djavan, et al., 1999a).
4.6.3 PSA in relation to prostate volume
(PSA density)
At a fixed serum PSA level the average pros-
tate volume has been shown to be smaller
in men with prostate cancer than in those
without (Bangma, et al., 1995b, Standaert,
et al., 1997, Kranse, et al., 1999). This is
due to the fact that prostate cancer tissue
(per gram tissue) releases about ten times
as much PSA to the circulation as BPH tis-
sue (Stamey, et al., 1987). Veneziano et al.
were the first to show that the accuracy of
serum PSA can be improved by dividing
the PSA value with the prostate volume
(Veneziano, et al., 1990). This finding has
been confirmed in later studies and the con-
cept is called PSA density (Benson, et al.,
1992, Bangma, et al., 1997, Rietbergen,
et al., 1998). Because the volume of the
transition zone (TZ) is preferentially en-
larged in BPH, serum PSA divided by TZ
volume has been considered more accurate
than PSA density (Kalish, et al., 1994,
Zlotta, et al., 1997, Djavan, et al., 1998,
Djavan, et al., 1999a). Some investigators
did not find any benefit of PSA density or
TZ density in comparison with serum PSA
alone (Brawer, et al., 1993, Lin, et al.,
1998). The yield of a standardized number
of prostate biopsies is smaller in large
glands (Uzzo, et al., 1995, Karakiewicz, et
al., 1997), and it has been speculated that
this is the basis for the diagnostic value of
PSA density and TZ density (Brawer,
1995). Prostate volume is an investigator-
Review of the literature
17
Detection of prostate cancer
dependent variable and this may affect the
diagnostic accuracy of PSA density.
4.6.4 Molecular forms of PSA in serum
PSA occurs in serum as non-complexed or
free PSA and in complex with various pro-
tease inhibitors (Lilja, et al., 1991, Stenman,
et al., 1991). When added to serum, intact
PSA rapidly forms complexes with α
2
-mac-
roglobulin (A2M) and to a smaller extent
with α
1
-antichymotrypsin (ACT) (Chris-
tensson, et al., 1990), and α
1
-protease in-
hibitor (API) (Leinonen, et al., 1996). Com-
plexes of proteases with A2M have a rapid
half time (2–5 minutes) in circulation. In
rats the half time of PSA-A2M has been
shown to be about 7 minutes (Birkenmeier,
et al., 1999). The major form of PSA in se-
rum is the complex with ACT which con-
stitutes 50–90% of all immuno-reactive
PSA. The proportion of PSA-ACT is higher
and the proportion of free PSA is lower in
serum from prostate cancer cases than in
men with BPH (Stenman, et al., 1991,
Christensson, et al., 1993, Leinonen, et al.,
1993). The proportions of free PSA and
PSA-ACT have repeatedly been shown to
reduce the frequency of false positive PSA
results by 20–30% in men with a serum PSA
above 4 µg/L (Catalona, et al., 1995, Partin,
et al., 1996, Reissigl, et al., 1996, Bangma,
et al., 1997, Catalona, et al., 1998), and to
reduce the number of false negative PSA
results when serum PSA is below 4.0 µg/L
(Catalona, et al., 1997, Lodding, et al.,
1998, Djavan, et al., 1999a, Törnblom, et
al., 1999). The proportion of free PSA is an
earlier predictor of a subsequent develop-
ment of prostate cancer than total PSA
(Pearson, et al., 1996), and it has also been
shown to predict the aggressiveness of the
cancer several years before clinical diagno-
sis (Carter, et al., 1997b, Arcangeli, et al.,
1998).
An assay measuring the complex between
PSA and API has recently been developed
(Zhang, et al., 1997), and about 1–10% of
serum PSA has been shown to be complexed
with API (Zhang, et al., 1999), but the true
concentration is somewhat smaller due to a
nonspecific background in the assay. The
proportion of PSA-API in serum is lower
in men with than in those without prostate
cancer (Zhang, et al., 1999). Assays for to-
tal PSA measure PSA-ACT, PSA-API, and
free PSA. Part of PSA in serum is complexed
to A2M, but due to encapsulation of PSA
in A2M this complex cannot be detected
by conventional immunological methods.
However, incubation at high pH denatures
A2M, and PSA in the complex and released
from it can be measured by a conventional
assay for PSA (Zhang, et al., 1998). Other
methods of determining PSA-A2M have
also been proposed (Espana, et al., 1996,
Lilja, et al., 1999). Among subjects with a
serum PSA of 4–10 µg/L the ratio of PSA-
A2M to total PSA is lower in prostate can-
cer cases (median 0.06) than in men with
BPH (median 0.12) and adds diagnostic in-
formation to the proportion of free PSA
(Zhang, et al., 2000).
4.6.5 Human kallikrein 2
Human kallikrein 2 (hK2) belongs to the
human glandular kallikrein protein family
and shows 80% homology with PSA both
at the protein and mRNA levels (Schedlich,
et al., 1987). Many antibodies detecting
total PSA have been shown also to detect
hK2 (Lövgren, et al., 1995). Several assays
for specific determination of hK2 in serum
have been developed (Piironen, et al., 1996,
Finlay, et al., 1998, Black, et al., 1999,
Becker, et al., 2000a). The serum concen-
trations of hK2 correlate with total and free
PSA (Piironen, et al., 1996, Recker, et al.,
1998, Magklara, et al., 1999). Both the se-
rum level of hK2 and the ratio between
hK2 and the proportion of free PSA have
been shown to correlate positively with
prostate cancer risk (Nam, et al., 2000), and
to increase the diagnostic accuracy for pros-
tate cancer at intermediate levels of serum
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PSA (Magklara, et al., 1999, Partin, et al.,
1999, Becker, et al., 2000b, Becker, et al.,
2000c). It is noteworthy that the ratio be-
tween hK2 and the proportion of free PSA
has been shown to add diagnostic informa-
tion to the proportion of free PSA at serum
PSA concentrations of 2.0–4.5 µg/L (Mag-
klara, et al., 1999, Partin, et al., 1999).
Both hK2 and the ratio between hK2 and
the proportion of free PSA can be used to
predict organ-confined disease and the dif-
ferentiation of the tumor independently of
total and free PSA (Haese, et al., 2000,
Recker, et al., 2000).
4.6.6 Insulin-like growth factor-I and its
binding proteins
Insulin-like growth factor-I (IGF-I) is a
mitogenic peptide that mediates the growth
promoting effect of growth hormone
(Daughaday and Rotwein, 1989). Elevated
serum concentrations of IGF-I have been
associated with both prostate cancer
(Mantzoros, et al., 1997, Chan, et al., 1998,
Wolk, et al., 1998), and BPH (Cohen,
1998). In serum the major part of IGF-I is
bound to one of its binding proteins,
IGFBP-3 (Martin and Baxter, 1992). The
serum concentrations of both IGF-I and
IGFBP-3 are mainly regulated by growth
hormone but also affected by nutritional
status, age, pregnancy and chronic disease
(Martin and Baxter, 1992). PSA has been
suggested to cleave IGFBP-3 (Cohen, et al.,
1992, Okabe, et al., 1999), leading to re-
lease of IGF-I. It has been speculated that
PSA causes release of IGF-I locally in the
prostate (Cohen, et al., 1994).
Chan et al. demonstrated in a serum bank
study with 152 prostate cancer cases and
152 matched controls that men in the high-
est quartile of serum IGF-I levels had a rela-
tive risk of prostate cancer of 2.4 in com-
parison with men in the lowest quartile
(Chan, et al., 1998). With adjustment for
the serum concentration of IGFBP-3 the
relative risk was 4.3. Two other case-con-
trol studies have shown a positive correla-
tion between serum IGF-I concentration
and prostate cancer risk (Mantzoros, et al.,
1997, Wolk, et al., 1998). In one of these
studies adjustment for the IGFBP-3 con-
centration was performed and this increased
the odds ratio of IGF-I for prostate cancer
(Wolk, et al., 1998). Other studies have not
shown higher serum IGF-I concentrations
in men with than in those without prostate
cancer (Cohen, et al., 1993, Kanety, et al.,
1993, Ho and Baxter, 1997). A recent study
indicated that IGF-I is not a useful marker
for prostate cancer (Cutting, et al., 1999).
whereas another study indicated diagnos-
tic usefulness of IGF-I when it is divided
by the concentration of serum PSA (Djavan,
et al., 1999b).
4.6.7 Statistical and mathematical methods
combining diagnostic information of multiple
variables
Logistic regression is a statistical method
especially suited for prediction of binary
outcomes (Hosmer and Lemeshow, 1989).
The linear predictor (x) given by the logis-
tic regression equation is fitted to the range
0–1 by a transformation [(ex/(1+ex)] and this
is an estimate of the probability of the out-
come. By logistic regression the diagnostic
value of individual variables can be esti-
mated, and variables with simultaneous
importance can be combined into a diag-
nostic algorithm. Logistic regression has
been used to construct diagnostic algo-
rithms for diagnosis of prostate cancer in
both clinical (Marley, et al., 1996, Opten-
berg, et al., 1997, Carlson, et al., 1998) and
screening settings (Standaert, et al., 1997,
Gomari, et al., 1998, Kranse, et al., 1999,
Virtanen, et al., 1999). Serum PSA, the pro-
portion of free PSA, DRE results, TRUS
findings, prostate volume, age, race and
family history of prostate cancer have been
included in the equations.
Artificial neural networks (ANNs) are
mathematical and statistical models that can
Review of the literature
19
Detection of prostate cancerReview of the literature
be optimized to recognize relationships
within data sets. An ANN can be trained to
diagnose prostate cancer (Gomari, et al.,
1998, Wei, et al., 1998, Virtanen, et al.,
1999). The most commonly used ANN in
clinical medicine is the multilayer percep-
tron (MLP) (Wei, et al., 1998). A larger num-
ber of parameters can more easily be included
in MLP than in logistic regression. This
brings flexibility to the optimization pro-
cess and ANNs can detect more complex re-
lationships within the data set than logistic
regression. In fact, as with logistic regres-
sion ANNs can also be made to fit the data
set perfectly. This is called overtraining or
overfitting, and it will ruin the general ap-
plicability of the the diagnostic model. To
avoid overtraining the training process can
be stopped when the fit of the model starts
to decrease in an external data set (early stop-
ping technique) (Bishop, 1995). Another
approach is to use Bayesian regularization
that in addition to the sum of squares of er-
rors also minimizes the sum of squares and
the number of the model parameters
(MacKay, 1992, Foresee and Hagan, 1997).
This is done after the variables have been nor-
malized (so that their standard deviation is
one) and orthogonalized.
Snow et al. were the first to develop a
neural network for prediction of prostate
biopsy outcome (Snow, et al., 1994). This
network was based on serum PSA, age,
DRE, and TRUS in men with a serum PSA
above 4 µg/L, and it showed 88% specific-
ity at 84% sensitivity. These results may
not be reproducible because the test set of
patients was used for early stopping of the
network training (Wei, et al., 1998).
Gomari et al. compared the capacity of lo-
gistic regression and three artificial neural
network models: learning vector quantiza-
tion (LVQ), MLP, and neurofuzzy network
to predict outcome of prostate biopsy in
screened men with a serum PSA of 3–10
µg/L (Gomari, et al., 1998). These diagnos-
tic models were based on various combina-
tions of age, total and free PSA, DRE,
TRUS, first-degree family history of pros-
tate cancer, and symptoms of the disease.
The LVQ model was more accurate than the
proportion of free PSA, the logistic regres-
sion and the MLP models, which did not
differ significantly from each other. Virtanen
et al. developed an MLP model based on
total and free PSA in serum, DRE, TRUS,
and family history of prostate cancer, but
the model was less accurate than a corre-
sponding logistic regression model (Virta-
nen, et al., 1999).
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5  Aims of the study
The aim of the present investigation was:
1) to develop methods for reducing the
number of false positive serum PSA results
in men screened for prostate cancer (II–IV)
2) to compare and assess the validity of vari-
ous diagnostic methods for prostate can-
cer among men with elevated serum PSA
(I–IV)
3) to identify variables that independently
predict the outcome of prostate biopsies and
to use these variables to construct diagnos-
tic models (III, IV).
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6  Materials and methods
6.1 Subjects (I–IV)
The subjects were identified within the
Finnish prostate cancer screening study
(Määttänen, et al., 1999), which is a part of
the European randomized study on prostate
cancer (Schröder and Bangma, 1997). The
subjects in the studies I–IV were screened
in 1996 and 1997. They were aged 55–67
years, and had a serum PSA concentration
of 4 µg/L or higher (Table 5). Because men
with a serum PSA < 4 µg/L did not undergo
prostate biopsy systematically, only those
with a serum PSA > 4 µg/L were included.
Of these, 6% lacked biopsy results for vari-
ous reasons. In the present investigation all
men without prostate cancer were used as a
control group, and among these the most
common biopsy finding was normal histol-
ogy (56%), followed by BPH (36%), pros-
tatitis (4%), prostatic intraepithelial neopla-
sia (2%), and other diagnoses (2%). Of the
prostate cancer patients 34%, 47%, 11%,
and 7% had a Gleason score of 2–4, 5–6, 7,
and 8–10, respectively. The frequency of
tumors with a low Gleason score is higher
than observed in another screening study
(Hoedemaeker, et al., 2000). The distribu-
tion of WHO grade was 42% grade I, 50%
grade II, and 8% grade III. The prostate
cancer was clinically localized to the pros-
tate gland (T0–T1M0) in 83%, locally ad-
vanced (T3–T4M0) in 12%, and metasta-
sized (T1–T4M1) in 5% of the cases.
6.2 Serum samples and laboratory
methods (I–IV)
Sera were kept frozen at –80oC and were
thawed once for analysis of total and free
PSA, immediately refrozen, and rethawed
for the analysis of IGF-I, IGFBP-3, and
PSA-API. The samples were analyzed in
random order blinded with regard to case-
control status.
The concentrations of total and free PSA
were measured simultaneously by a dual
label time-resolved immunofluorometric
assay (Prostatus, EG&G-Wallac) (Mitrunen,
et al., 1995). Total PSA was also determined
with the Beckman-Hybritech Tandem-E
method which correlates strongly with the
Prostatus method (Blijenberg, et al., 1997).
In this study the results of the Prostatus
method were used.
Total serum IGF-I was measured by a
sandwich-type immunoassay (Active IGF-I
ELISA, DSL-10-5600, Diagnostic Systems
Laboratories, Inc., Webster, TX). The assay
uses acid-ethanol extraction to dissociate
IGF-I from its binding proteins. Serum
IGFBP-3 was measured by an immuno-
fluorometric assay (IFMA) using mono-
clonal antibodies (1B6/5C11) against re-
combinant IGFBP-3 (Koistinen, et al.,
1994). The assay detects only intact
IGFBP-3 and shows no cross-reactions with
the other human IGFBPs or IGFs. IGF-I
Study
Men with prostate cancer (n)
Men without prostate cancer (n)
All subjects (n)
Range of serum PSA (µg/L)
I
179
486
665
≥ 4
II
78
226
304
≥ 4
III
200
558
758
4–20
IV
148
508
656
4–10
Table 5. Number of subjects and their PSA concentra-
tions in the original publications.
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and IGF-II do not interfere with the assay
(Koistinen, et al., 1994).
The serum concentration of PSA-API was
measured with an immunofluorometric as-
say with a monoclonal antibody (H117) to
total PSA on the solid phase and a polyclonal
antibody to API as the detector antibody
(Zhang, et al., 1999). For each sample the
nonspecific background signal (produced by
nonspecific binding of the huge amount of
API to the solid phase) was measured with
an assay using an unrelated solid-phase an-
tibody but the same detector antibody. By
subtracting the signal caused by the non-
specific binding of API the detection limit
of the assay could be improved. The bio-
logical detection limit of the assay was es-
timated as the mean value plus 2 SD of PSA-
API measured in sera from 42 females. Pa-
tients with a serum PSA-API value below
this were given a value of half the detection
limit (0.025 µg/L).
6.3 DRE, prostate volume and prostate
biopsies (I–IV)
Clinical investigation of the patients was
performed by several urologists in four
medical centers. DRE was defined as posi-
tive if any abnormality was palpated. Pros-
tate volume was estimated by TRUS accord-
ing to the formula (π/6) x (transverse di-
ameter x anteroposterior diameter x cepha-
locaudal diameter) (Terris and Stamey,
1991). Sextant biopsies of the prostate were
taken under TRUS guidance, and additional
biopsies were obtained from suspicious le-
sions identified by TRUS or DRE. Men
without cancer in the first biopsy were
rebiopsied within six months if the concen-
tration of serum PSA was higher than 10
µg/L or if they had high grade prostatic in-
traepithelial neoplasia.
6.4 Statistical methods
6.4.1 General (I–IV)
The Mann-Whitney U test was used to
compare the distribution of age, serum to-
tal PSA, the proportion of free PSA, IGF-I,
IGFBP-3, PSA-API, and prostate volume
between cases and controls. The difference
in distributions of binary variables (DRE
findings, and family history of prostate can-
cer) between cases and controls were assessed
by the chi square test. Correlations between
continuous variables were estimated by par-
tial correlation (I), and by calculating
Pearson’s correlation coefficient (II). When
necessary, the variables were logarithmically
transformed to achieve normal distribution
before analyses of correlations. The differ-
ence in serum PSA-API levels in sera from
42 females before and after background ex-
traction was tested by Wilcoxon matched-
pairs signed-ranks test (II). To evaluate the
diagnostic validity of the variables, clinical
sensitivity, specificity (I-IV), positive pre-
dictive value, and negative predictive value
were calculated (IV) (Table 6). Specificities
at various levels of sensitivity were com-
pared by the McNemar test (II, III). To
evaluate the diagnostic accuracy of various
Concept
Specificity
Sensitivity
Negative predicitve value
Positive predictive value
Accuracy
Table 6. Explanations for various concepts describing diagnostic validity.
Definition
Proportion of subjects without disease who have a negative test
Proportion of subjects with disease who have a positive test
Proportion of subjects with a negative test who do not have the disease
Proportion of subjects with a positive test who have the disease
Proportion of subjects with a correct test result
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diagnostic tests, receiver-operating charac-
teristic (ROC) curves were constructed and
the area under the curve (AUC) was calcu-
lated according to the method of Hanley
and McNeil (I, II) (Hanley and McNeil,
1982). The AUC represents the probabil-
ity of a randomly selected case patient to
have a higher value than a randomly selected
control patient. If the AUC is 0.5 the diag-
nostic test is of no value and if AUC is 1
the test is perfect.
6.4.2 Logistic regression (I–IV)
Multiple logistic regression analysis was
used to identify and quantify the diagnostic
value of variables that simultaneously affect
the probability of having prostate cancer.
The binary response variable in the logistic
regression analyses was presence or absence
of prostate cancer in prostate biopsy (I–IV).
Explanatory variables were the concentra-
tion of total PSA in serum (I-IV), age (I, III,
IV), serum IGF-I (I), serum IGFBP-3 (I),
prostate volume (I, III, IV), the proportion
of free PSA (II–IV), the concentration of
PSA-API (II), DRE findings (III–IV), and a
family history of prostate cancer (father or
brother having prostate cancer) (III–IV).
Various transformations (logarithmic, qua-
dratic, square root, categorical, and dichoto-
mous) of continuous explanatory variables
were tested in order to achieve a better fit of
the model as assessed by the Hosmer-
Lemeshow test and the deviance of the model
(Hosmer and Lemeshow, 1989). No first or
higher order interactions were found be-
tween any of the explanatory variables. Prob-
abilities of having prostate cancer in biop-
sies were calculated on the basis of the lo-
gistic regression models (II–IV). 95% con-
fidence intervals (CI) of these probabilities
were calculated with SAS 6.12 for Windows.
Other analyses were performed with SPSS
6.0 for the Macintosh. Odds ratios of pros-
tate cancer for various variables were ob-
tained by calculating the exponents of the
regression coefficients of the variables.
6.4.3. MLP with Bayesian regularization
(IV)
The neural network model used (IV) was an
MLP network composed of one input layer
with four preprocessed variables (total PSA,
the proportion of free PSA, prostate volume
and DRE), one hidden layer with two neu-
rons, and one output layer with one neuron
giving the output value that is a measure of
the probability of cancer (Figure 1). The four
input variables were normalized so that their
standard deviations were 1 and orthogonal-
ized by principal component analysis
(Bishop, 1995), which has the capability to
reduce the number of input variables but
did not do so in this study. The network
model contained 13 parameters (weights) to
be optimized. The activation function used
in the hidden layer and the output layer was
the hyperbolic tangent sigmoid function
[a=tanh(s)=(es–e-s)/(es+e-s)] that generates
output values (a) between –1 and 1; s is the
weighted sum of preceding neuron outputs.
X1
Figure 1. Schematic picture of the MLP model used.
X1–X4 represent the input variables (total PSA, the
proportion of free PSA, DRE and prostate volume). IW
stands for input weight, IB for input bias, LW for layer
weight, and LB for layer bias.
X2
X3
X4
IW1,1
IW1,2
IW2,1
IW2,2
IW3,1
IW3,2
IW4,1
IW4,2
Bias
IB2
Input
layer
Hidden
layer
Output
layer
Σ
Σ
Σ
Bias
IB1 Bias
LB
LW1
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The formula for the whole network in Fig-
ure 1 can be written mathematically as fol-
lowing:
a1 = tanh(IW1,1*X1 + IW2,1*X2 + IW3,1*X3 + IW4,1*X4 + IB1)
a2 = tanh(IW1,2*X1 + IW2,2*X2 + IW3,2*X3 + IW4,2*X4 + IB1)
a
out = tanh(LW1*a1 + LW2*a2 + LB)
where a
1
 and a
2
 are the outputs of the hid-
den neurons and a
out
 is the output of the
network. After the model building, the out-
put value was linearly transformed into the
range 0–1. The network was trained using
Levenberg-Marquardt optimization com-
bined with Bayesian optimization of the
regularization parameters (Foresee and
Hagan, 1997). The aim of regularization is
to avoid overtraining of the model by mini-
mizing the sum of squares of errors and the
sum of squares of model parameters. The
Bayesian technique controls the regulariza-
tion so that these two minimizing processes
occur in a balanced manner (MacKay, 1992,
Foresee and Hagan, 1997).
Suitable initial weights for the MLP
model were estimated by randomly divid-
ing the 655 (656–1) patients in each train-
ing set into two groups. The model was ini-
tially fitted on 75% and tested on 25% of
the patients in the training set. The random-
Materials and methods
ization, fitting and testing sessions were re-
peated 5 times and the weights producing
the smallest sum of squared errors on the
initial test set were selected as initial weights
for the final training of the MLP. The MLP
models were optimized with the MATLAB
Neural Network Toolbox, version 3.
6.4.4. Validation of diagnostic models (II, IV)
The generalizability of the diagnostic mod-
els were assessed by cross validation (II) and
leave-one-out validation (IV) (Moody and
Utans, 1995). The patients were divided
into a training set (with all minus n pa-
tients) and a test set with n patients. The
training and testing sessions were repeated
till every patient had been a part of the test
set once. In the cross validation in study
(II) the patients were randomly divided into
four groups and consequently trained on
75% and tested on 25% of the patients. This
was repeated four times. In leave-one-out
validation n is one, and as the study (IV)
comprised 656 patients there were 656
rounds of training and testing. To obtain a
desired sensitivity level among the tested
subjects, a cut-off of the output value was
determined on the basis of the respective
sensitivity level in the training set.
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7  Results
7.1 IGF-I and IGFBP-3 in serum of
patients with elevated serum PSA (I)
7.1.1 Correlations between variables and
differences between diagnostic groups.
The serum concentration of IGF-I corre-
lated positively with serum IGFBP-3 and
prostate volume but was not associated with
the serum PSA level (Table 7). Serum IGF-
I and IGFBP-3 correlated negatively with
the age of the patients. There was no sig-
nificant difference in mean age (62 vs. 63
years; p=0.122), serum IGF-I (183 vs. 194
µg/L; p=0.094) or IGFBP-3 (4 600 vs.
4 500 µg/L; p=0.948) between prostate
cancer cases (n=179) or men without pros-
tate cancer (n=486). The median concen-
tration of serum PSA (8.3 vs. 5.7 µg/L;
p<0.001) was higher, whereas prostate vol-
ume was lower (28 vs. 38 mL; p<0.001)
among cases than controls.
7.1.2 Odds ratios of serum IGF-I and
IGFBP-3 for prostate cancer
Men with a high serum IGF-I concentra-
tion (highest quartile of IGF-I concentra-
tions) had a smaller risk of having prostate
cancer on biopsy than those with a low se-
rum IGF-I concentration (lowest quartile)
when adjusting for the confounding effect
of serum IGFBP-3, serum PSA, and age
(OR 0.50; 95% CI 0.26–0.97) (Table 8).
When also adjusting for prostate volume
the association between serum IGF-I level
and prostate cancer risk was weaker and no
longer statistically significant.
1
2
3
4
1Adjusted for age and serum PSA
2Adjusted for age, serum PSA, and serum IGFBP-3
3Adjusted for age, serum PSA, serum IGFBP-3, and prostate volume
4Per 160 µg/L increment of serum IGF-I concentration
*p<0.05 for difference between first and fourth quartile
IGF-I continuous4
IGF-I quartile
< 134
134–186
187–242
> 242
Range (µg/L)
1.00
0.76
0.62
0.60
reference
(0.45–1.26)
(0.36–1.07)
(0.34–1.04)
0.63 (0.41–0.96)
OR1 (95% CI)
1.00
0.71
0.56
0.50
reference
(0.42–1.20)
(0.32–1.00)
(0.26–0.97)*
0.51 (0.30-0.86)
OR2 (95% CI)
1.00
0.75
0.60
0.57
reference
(0.42–1.35)
(0.32–1.10)
(0.28–1.16)
0.61 (0.34-1.09)
OR3 (95% CI)
Table 8. Odds ratio of prostate cancer in relation to quartiles of serum IGF-I concentration.
Age
IGF-I
IGFBP-3
Total PSA
Prostate volume
-0.16
0.60
0.00
0.09
< 0.001
<0.001
0.983
0.021
-0.20
0.60
0.00
0.03
< 0.001
< 0.001
0.954
0.456
IGF-I IGFBP-3
r P value r P value
Table 7. Correlations (r) between serum IGF-I, IGFBP-
3, age and prostate volume among subjects with a
serum PSA of 4 µg/L or higher.
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7.1.3 Serum IGF-I and IGFBP-3 as
diagnostic tests for prostate cancer
As evidenced by ROC analysis the number
of false positive PSA results could not be
reduced by using serum IGF-I or IGFBP-3
as diagnostic tests. The areas under the ROC
curve, 0.55 for IGF-I and 0.50 for IGFBP-3,
did not differ statistically significantly from
0.50, which is the AUC of a test without
diagnostic value (Figure 2).
7.2 PSA-API in serum of patients with
elevated serum PSA (II)
7.2.1 Subtraction of the nonspecific back-
ground in the PSA-API assay
In 42 female sera without PSA immunore-
activity, the PSA-API concentration was
measured both with a PSA antibody and an
unrelated antibody (to human chorionic
gonadotropin) on the solid phase. The ap-
parent mean concentration of PSA-API in
female sera measured by the two methods
did not differ significantly from each other
(0.09 vs. 0.08 µg/L; p=0.17). Thus, the
nonspecific background could be eliminated
by subtraction. The biological detection
limit of the assay with background subtrac-
tion was 0.05 µg/L, as compared to 0.21
µg/L without extraction.
7.2.2 PSA-API and free PSA in serum from
men with a serum PSA of 4–10 µg/L
In men with a serum PSA concentration of
4–10 µg/L the proportion of free PSA and
PSA-API in serum were lower in men with
prostate cancer than in those without
(Table 9). The concentration of serum PSA
did not differ between prostate cancer cases
and controls. There was no correlation be-
tween the proportions of free PSA and PSA-
API (r=0.03, p=0.56) among men with a
serum PSA of 4 to 10 µg/L. Of the cancer
cases 42 of 44 had a proportion of free PSA
lower than 25%. Only 7% of the cancer
Results
Sensitivity
1 – Specificity
IGF-I, AUC = 0.55
IGFBP-3, AUC = 0.50
0.0
0.2
0.4
0.6
0.8
1.0
1.00.80.60.40.20.0
Figure 2. ROC analysis of serum IGF-I and IGFBP-3.
*95% confidence intervals for the median
Table 9. Medians and 95% confidence intervals of the concentrations and proportions of the various forms of PSA
in serum from subjects with serum PSA in the range 4–10 µg/L.
Prostate cancer
Benign
P value
44
210
Patient group N
5.5 (4.9–6.6)
5.4 (5.1–5.6)
0.28
Total PSA (µg/L)
Median (95% CI*)
13.0 (10.8–15.3)
19.2 (18.1–20.6)
< 0.001
PSA-F/T (%)
Median (95% CI*)
0.053 (0.025–0.278)
0.091 (0.025–0.503)
0.012
PSA-API, µg/L
Median (95% CI*)
0.78 (0.53–1.63)
1.61 (1.46–1.76)
0.002
PSA-API/T (%)
Median (95% CI*)
Key: PSA-F/T = proportion of free PSA; PSA-API/T = proportion of PSA-API
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cases, but 20% of the controls with a pro-
portion of free PSA lower than 25% had a
proportion of PSA-API higher than 2.5%
(Figure 3). Logistic regression analysis
showed that the proportion of free PSA and
the concentration of PSA-API were simul-
taneously significant diagnostic variables
(p<0.001 and p=0.009, respectively). The
diagnostic information of these two variables
was combined by using logistic regression
to calculate the probability of prostate can-
cer. At high sensitivity levels this probabil-
Results
ity had a higher specificity than the propor-
tion of free PSA (Table 10). In ROC analy-
sis the AUCs of the proportion of free PSA
(0.73) and the probability of prostate can-
cer estimated by logistic regression (0.75)
were not significantly different (p=0.58).
7.3 Estimation of probability of detect-
ing prostate cancer on biopsy (III)
7.3.1 Selection of important diagnostic
variables
Men with a serum PSA of 4 to 20 were in-
cluded in the study (III) in order to enable
identification of patients with a low prob-
ability of prostate cancer although their se-
rum PSA was 10–20 µg/L. There was no
significant difference in age distribution (62
vs. 63 yrs; p=0.118) or frequency of a fam-
ily history of prostate cancer (5.7% vs.
7.9%; p=0.371) between the prostate can-
cer cases (n=200) and controls (n=558). The
median serum concentration of total PSA
(6.8 vs. 5.5 µg/L; p<0.001) and frequency
of positive DRE findings (37% vs. 12 %;
p<0.001) were higher, whereas the propor-
tion of free PSA 14% vs. 20%; p<0.001)
and prostate volume (33 mL vs. 42 mL;
p<0.001) were lower among cases than con-
trols. When variables were selected into the
logistic regression equation by forward and
backward stepwise methods, serum PSA,
the proportion of free PSA, prostate volume
and DRE findings were retained in the
Proportion of free PSA (%)
Proportion of PSA-API (%)
Figure 3. The proportion of PSA-API as a function of
the proportion of free PSA in serum from men with a
serum PSA of 4–10 µg/L.The broken lines denote a
cutoff of 2.5% for the proportion of PSA-API and 25%
for the proportion of free PSA.
50403020100
0
1
2
3
4
5
6
7
8
Controls
Prostate cancer
cases
95
90
85
Table 10. Clinical sensitivities and specificities of the concentration of total PSA in serum, the proportions of PSA-
API and free PSA, and LR (probability of prostate cancer calculated by logistic regression to combine the diagnostic
information of PSA-API and the proportion of free PSA) in prostate cancer patients (n = 44) and controls (n = 210)
with serum PSA concentrations of 4–10 µg/L.
Specificity (%) Significances (p values) of
differences in specificities of:
Sensitivity
(%)
0.082
<0.001
0.337
PSA-API/T
vs. total PSA
<0.001
<0.001
0.038
PSA-F/T
vs. total PSA
<0.001
<0.001
<0.001
LR vs.
PSA-F/T
5
6
22
10
21
27
26
28
33
41
42
52
Total PSA PSA-API/T PSA-
F/T
LR* of PSA-API
and PSA-F/T
Key: PSA-F/T = proportion of free PSA; PSA-API/T = proportion of PSA-API.
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model (Table 11). As evidenced by the larg-
est deviance increase if excluded from the
model, the proportion of free PSA was the
most important diagnostic variable. Pros-
tate volume was used as a binary variable
for purposes of presentation, but even if used
as a continuous variable its deviance increase
was the smallest.
7.3.2 Probability of cancer detection on biopsy
Of the subjects with a serum PSA of 4.0–
4.5 µg/L 18% had prostate cancer, indicat-
ing that the overall probability of prostate
cancer when serum PSA is 4 µg/L is about
0.18. The probability, as calculated by lo-
gistic regression analysis, was lower in cases
with a high proportion of free PSA, a large
prostate volume (> 37 mL), and when the
DRE findings were negative (Table 12). The
probability of prostate cancer increased with
increasing serum PSA concentration, but a
two-fold increase in serum PSA (from 4 to
10 µg/L or from 10 to 20 µg/L) increased
the probability less than a decrease of 10
percent units in the proportion of free PSA.
The probability of having prostate cancer
of subjects with a prostate volume below
37 mL was 1.1 to 2-fold that of subjects
with a larger prostate volume. A positive
DRE finding increased the probability of
detecting prostate cancer 1.2–3-fold. The
mean probability (calculated before biopsy)
of detecting prostate cancer was 0.41 (95%
CI 0.38–0.44) for prostate cancer cases and
0.21 (95% CI 0.20–0.22) for controls (Fig-
ure 4).
7.4 Predicting outcome of prostate
biopsy by using an MLP network (IV)
7.4.1 Diagnostic variables among subjects
with a serum PSA of 4–10 µg/L
Among men with a concentration of serum
PSA of 4–10 µg/L there was a significant
difference in serum PSA level (5.7 vs. 5.3;
p=0.036), proportion of free PSA (15% vs.
21%; p<0.001), prostate volume (32 mL
vs. 42 mL; p<0.001) and frequency of posi-
ln(PSA-T, µg/L)
PSA-F/T, 10 percent units
DRE
Prostate volume ≥ 37 mL
Intercept
Deviance = 719.8
Hosmer-Lemeshow test, p = 0.94
Table 11. Logistic regression equation used to calculate the probabilities in table 12.
0.001
<0.001
<0.001
0.002
10.5
41.6
22.2
9.6
0.247
0.163
0.217
0.205
0.563
0.80
-0.96
1.03
-0.63
-0.86
Variable P ValueDeviance increase*Standard errorCoefficient (ß)
*The impact of the variables is reflected by the deviance increase if the variable is excluded from the model. Larger
numbers denote a stronger impact of the variable.
Table 12. Probability of detecting prostate cancer at
biopsy for a negative and positive DRE, a low or high
prostate volume, and for various concentrations of total
PSA and proportions of free PSA. The probabilities are
based on the equation in Table 11.
DRE –, Volume ≥37 mL
Probability
PSA-T (µg/L)
DRE +, Volume ≥37 mL
0.60
0.37
0.18
0.08
20
0.47
0.25
0.11
0.05
10
0.30
0.14
0.06
0.02
4
0.54
0.31
0.15
0.06
4
0.71
0.48
0.27
0.12
10
0.81
0.62
0.39
0.19
20
5
15
25
35
F/T (%)
DRE –, Volume <37 mL
PSA-T (µg/L)
Probability
DRE +, Volume <37 mL
0.74
0.52
0.30
0.14
20
0.62
0.39
0.20
0.09
10
0.44
0.23
0.10
0.04
4
0.69
0.46
0.25
0.11
4
0.82
0.64
0.41
0.21
10
0.89
0.76
0.54
0.31
20
5
15
25
35
F/T (%)
Key: F/T = proportion of free PSA
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tive DRE findings (28% vs. 11%; p<0.001)
between prostate cancer cases (n=148) and
controls (n=508), whereas there was no dif-
ference in age distribution (62 vs. 63 yrs;
p=0.168) or frequency of a family history
of prostate cancer (5.9% vs. 5.9%; p=
0.937). All four variables that were signifi-
cant in univariate analysis were found to be
simultaneously significant diagnostic vari-
ables in a logistic regression model. These
Probability of prostate cancer detection
1.00.20 0.40 0.60 0.800
180
160
140
120
100
80
60
40
20
0
Subjects without prostate cancer (n)
0.20 0.40 0.60 0.80 1.00
180
160
140
120
100
80
60
40
20
0
Subjects with prostate cancer (n)
Probability of prostate cancer detection
Figure 4. Distribution of the calculated probability of prostate cancer detection at biopsy among men with (n=200)
and without prostate cancer (n=558).
variables were also used to construct a neu-
ral network model (MLP).
7.4.2 Accuracy of the diagnostic
models and the proportion of free PSA
At sensitivity levels of 90–100% the MLP
model was more accurate than the logistic
regression model, and both models were
more accurate than the proportion of free
Table 13. Diagnostic performance of the proportion of free PSA, the LR and MLP models in 148 prostate cancer
cases, and 508 controls with a serum PSA concentration of 4–10 ng/mL.
Key: F/T = proportion of free PSA; LR = logistic regression model; P1 = P Value (McNemar test) for difference in
accuracy between LR and F/T; P2 = difference between MLP and F/T; P3 = difference between MLP and LR.
Target sensitivity is the sensitivity aimed at in the training session; the actual sensitivity is the sensitivity obtained in
the testing session. To make the various algorithms comparable the proportion of free PSA has been treated in the
same way (with target and actual sensitivity) as the diagnostic models based on logistic regression and MLP.
100
95
90
85
80
<0.001
0.002
0.017
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.001
<0.001
0.001
0.651
0.201
Target
sensitivity
Actual
sensitivity Specificity Accuracy P1 P2 P3
F/T
23
36
49
51
56
LR
30
40
52
59
63
MLP
33
47
56
59
62
F/T
1
19
38
47
50
LR
9
24
41
52
59
MLP
13
33
46
53
57
F/T
99
95
90
85
80
LR
99
95
89
84
78
MLP
99
95
89
82
79
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PSA (Table 13). If missing 5% of the can-
cer cases was accepted (95% sensitivity) the
MLP model reduced 33%, the logistic re-
gression model 24%, and the proportion of
free PSA 19% of the false positive PSA re-
sults. At lower sensitivity levels (80–85%)
the MLP and logistic regression models
performed equally, but both had a higher
specificity (reduced more false positive PSA
results) than the proportion of free PSA.
Results
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8  Discussion
The goal of prostate cancer screening is to
reduce mortality and morbidity in prostate
cancer. However, screening with serum PSA
has not yet been proved to achieve this goal
in randomized trials.
8.1 PSA and prerequisites for
screening
Principles for early disease detection have
been suggested by Wilson and Jungner
(Wilson and Jungner, 1968). 1) The dis-
ease should be an important health prob-
lem. 2) There should be an accepted treat-
ment available. 3) The natural history of the
disease should be adequately understood and
the disease should have a preclinical phase.
4) There should be a valid test available that
is acceptable to the population and results
in earlier detection of the disease. 5) The
cost of screening and treatment should be
economically possible and the screening
should be a continuous process.
PSA-based screening fulfills most, but
not all, of the above mentioned prerequi-
sites for a successful screening program.
First, prostate cancer is a major health prob-
lem. It is the most common cancer among
Finnish men with an incidence of 72 new
cases/100 000 person-years in 1997, and it
is the second most common cause of cancer
death among men. Second, treatment of
prostate cancer by radical prostatectomy and
radiation therapy is effective if the disease
is localized to the prostate gland. However,
radical treatment causes complications.
Third, the natural history of prostate can-
cer is fairly well known. Prostate cancer is a
slowly growing disease, and therefore
screening and treatment of men with a short
life expectancy is not likely to reduce pros-
tate cancer specific mortality (Albertsen, et
al., 1998, Carter, et al., 1999). Most pros-
tate cancers have a long latent phase and do
not develop into clinical disease during the
patient’s life time. Thus it is inevitable that
prostate cancer screening will lead to de-
tection and treatment of some prostate can-
cers that would not otherwise have been
diagnosed during the patient’s life time.
Fourth, the PSA test is available and accept-
able to the population. PSA-based screen-
ing has been estimated to result in a lead
time for detection of prostate cancer of about
5 to 10 years (Stenman, et al., 1994, Gann,
et al., 1995). Most prostate cancers detected
on the basis of an elevated PSA are clini-
cally relevant, organ-confined and poten-
tially curable (Catalona, et al., 1993). How-
ever, the majority of men with a positive
PSA test do not have prostate cancer at bi-
opsy, and this has been considered to be the
principal drawback of PSA testing (Smith,
et al., 2000).
The screening should also improve the
outcome of the disease, and do more good
than harm. A screening study in Quebec
reported a reduction in prostate cancer mor-
tality of 69% (Labrie, et al., 1999). How-
ever, the study participants were not prop-
erly randomized into screening and control
arms, and the study has been criticized for
being heavily biased in several ways
(Alexander and Prescott, 1999, Boer and
Schröder, 1999). The true effect of prostate
cancer screening will hopefully be clarified
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by ongoing randomized prostate cancer
screening trials (Auvinen, et al., 1996).
8.2 Existing methods for reducing the
number of false positive PSA results
The aim of the present investigation was to
develop methods by which the number of
false positive serum PSA results can be re-
duced. This is important because more than
two thirds of the subjects with an elevated
PSA do not have prostate cancer on biopsy.
Needle biopsy is complicated by infection
or bleeding in 0.1 to 4%, and by discom-
fort and anxiety in 58 to 68% of the pa-
tients (Cooner, et al., 1990, Aus, et al.,
1993, Desmond, et al., 1993). Waiting for
the biopsy result also causes anxiety. Increas-
ing the cutoff value of serum PSA would
lead to a reduction of the number of false
positive PSA results, but this would not
serve the goal of the screening as the num-
ber of curable cancers detected would de-
crease.
The proportions of free PSA and PSA-
ACT can be used to reduce the number of
false positive PSA results by 20 to 30% in
the serum PSA range 4 to 10 µg/L with little
or no decrease in the number of detected
cancer cases (Reissigl, et al., 1996, Cata-
lona, et al., 1998). Among men with an el-
evated concentration of serum PSA, pros-
tate volume has been shown to be smaller
among those with than those without pros-
tate cancer. This finding has formed the
basis for PSA density. PSA density has been
claimed to reduce as many false positive PSA
results as the proportion of free PSA
(Bangma, et al., 1997), but it is available
only when TRUS has been performed. Fur-
thermore, many urologists prefer to always
take biopsies when performing TRUS. In
this case TRUS findings and prostate vol-
ume are not utilized when deciding whether
to perform a biopsy. It is not clear whether
prostate volume is useful when combined
with the proportion of free PSA because a
large prostate volume may increase the per-
centage of free PSA. The present investiga-
tion showed a positive correlation between
the proportion of free PSA and prostate vol-
ume, but logistic regression analysis indi-
cated that they still are simultaneously im-
portant as diagnostic variables (III, IV).
Thus, prostate volume can be used to im-
prove the detection of prostate cancer even
when free and total PSA are available.
Before the PSA era DRE was the main
screening tool for prostate cancer. DRE is a
less sensitive test than PSA, but among men
with a serum PSA of 4 to 10 µg/L a clearly
larger proportion of the men with prostate
cancer has a positive DRE finding (28%)
than men without prostate cancer (11%)
(IV). A problem with DRE is the large in-
ter-observer variation (Schröder, et al.,
1998). However, although several urologists
performed the DRE:s in the present inves-
tigation, the DRE result was an indepen-
dently important diagnostic variable, which
the finding of a hypo-echoic area by TRUS
was not. The validity of our diagnostic al-
gorithms could possibly be improved if
DRE would be performed in a systematic
manner by persons specifically trained to
achieve inter-observer agreement (Varen-
horst, et al., 1993, Schröder, et al., 1998).
A family history of prostate cancer has
been shown to be an important risk factor
for prostate cancer (Walsh and Partin,
1997). However, in the present investiga-
tion (III) the frequency of subjects with a
first degree familial prostate cancer (brother
or father with prostate cancer) was similar
(6 vs. 8%) in men with and without pros-
tate cancer. This finding is surprising espe-
cially as a recent study on 44 788 pairs of
twins in Sweden, Denmark, and Finland
showed that heritability has a substantial
effect on prostate cancer risk: as much as
42% of the prostate cancer risk may be ex-
plained by heritable factors (Lichtenstein,
et al., 2000). Our finding could possibly be
explained by the fact that the subjects were
selected on the basis of an elevated serum
PSA. However, an accumulation of a fam-
Discussion
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ily history of prostate cancer among pros-
tate cancer cases has been observed in screen
positive subjects in other countries (Virta-
nen, et al., 1999).
The prevalence of prostate cancer in-
creases strongly with age. Age-specific cut-
off values for PSA have been proposed
(Oesterling, et al., 1993), but there are
strong arguments for the use of a constant
PSA cutoff for all age groups (Etzioni, et
al., 1996, Carter, 2000), and instead de-
creasing the intensity of the screening
among older men by prolonging the test
intervals (Carter, et al., 1999). Because age
is a risk factor for prostate cancer, age has
been used to assist in the biopsy decision in
some studies (Chen, et al., 1996, Opten-
berg, et al., 1997). In our study and some
other ones comprising a limited age range
the correlation between age and prostate
cancer risk was not statistically significant
(Kranse, et al., 1999, Virtanen, et al., 1999).
8.3 Serum IGF-I
Because serum IGF-I has been suggested to
be associated with an increased risk of pros-
tate cancer (Mantzoros, et al., 1997, Chan,
et al., 1998, Wolk, et al., 1998), we decided
to determine whether serum IGF-I can be
used to reduce false positives PSA results.
In our study population that included men
with a serum PSA of 4 µg/L or higher, se-
rum IGF-I was slightly but not significantly
lower among men with prostate cancer than
in those without. This was possibly partly
explained by a weak positive correlation
between serum IGF-I concentration and
prostate volume, which was larger in con-
trols than in cases. Recently, a strong asso-
ciation between high IGF-I levels, BPH and
enlarged prostate volume was observed in
acromegaly patients with elevated serum
concentrations of growth hormone and
IGF-I, whereas successfully treated patients
had normal prostate volume and growth
hormone deficient cases had reduced pros-
tate volume (Colao, et al., 1999). These find-
ings indicate that a high serum IGF-I may
cause BPH. A causal link between serum
IGF-I and prostate volume could explain
the positive correlation between serum PSA
and prostate cancer in earlier studies (Cohen,
1998). Before the PSA era prostate cancer
was often detected because of urinary symp-
toms, which mainly are caused by BPH and
an enlarged prostate. It has even been sug-
gested that the positive correlation between
serum IGF-I and prostate cancer risk seen
in some studies may be due to a bias caused
by prostate volume (Cohen, 1998). In ear-
lier studies on the correlation between se-
rum IGF-I and prostate cancer risk, pros-
tate volume has not been measured and the
controls have not been selected on the basis
of an elevated PSA value. We could study
the effect of prostate volume and when sta-
tistically adjusting for prostate volume the
negative correlation between serum IGF-I
and prostate cancer risk became weaker. The
conclusion of our study is that serum IGF-I
not is a useful marker for reducing the num-
ber of false positive PSA results in a screen-
ing setting (I). Furthermore, our findings
support the notion that serum IGF-I is as-
sociated with prostate volume rather than
with prostate cancer (Colao, et al., 1999).
8.4 Serum PSA-API
The proportion of PSA-ACT is larger
(Stenman, et al., 1991), whereas the pro-
portions of free PSA and PSA-API are
smaller in men with prostate cancer than
in those without (Zhang, et al., 1999). Thus
PSA-API is a potentially useful marker for
prostate cancer. However, the original as-
say for PSA-API was hampered by a non-
specific background, which limited its sen-
sitivity. The background signal is caused by
the large excess of serum API that binds
nonspecifically to the solid phase as such or
possibly in complex with other proteases.
A complex between ACT and cathepsin G
is thought to cause the nonspecific back-
ground in assays for PSA-ACT (Heidtmann
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and Havemann, 1993, Pettersson, et al.,
1995). The PSA-API assay used in the
present investigation was improved by sub-
tracting the nonspecific background caused
by binding of API to the solid phase. Thus
the detection limit could be lowered and
PSA-API could be determined in most of
the subjects with a serum PSA of 4 to 10
µg/L. The new assay is a bit more laborious
than a conventional PSA assay, requiring the
performance of one assay for PSA-API and
one for the background signal. However,
both assays can easily be performed on an
automatic analyzer.
Most cancer cases (95%) with a serum
PSA of 4–10 µg/L had a proportion of free
PSA below 25%, but so had most controls
(78%) too. A high proportion of PSA-API
indicated a low probability of prostate can-
cer although the proportion of free PSA was
lower than 25%. Seven percent of the can-
cer cases with a proportion of free PSA be-
low 25% had a proportion of PSA-API
higher than 2.5% as compared to 20% of
the controls. We could therefore combine
the diagnostic information of PSA-API and
the proportion of free PSA using logistic
regression analysis to calculate the probabil-
ity of prostate cancer, and at high sensitiv-
ity levels this combination could reduce
more false positive PSA results than the
proportion of free PSA alone.
8.5 Optimal use of available variables
to reduce false positive PSA results
Logistic regression is a statistical technique
that can be used to identify among mul-
tiple variables those which provide indepen-
dent diagnostic information. Logistic re-
gression can also be used to construct diag-
nostic algorithms for estimating the prob-
ability of a disease. This probability opti-
mally combines the diagnostic information
of the variables in the logistic regression
equation. In some types of data sets even
more optimal combinations can be achieved
by neural networks that are more complex
mathematical models than logistic regres-
sion. Diagnostic algorithms based on logis-
tic regression and neural networks facilitate
the interpretation and utilization of mul-
tiple diagnostic variables.
In the present investigation we showed
by logistic regression analysis that the vari-
ables that contribute simultaneously to the
diagnostic information among men with a
serum PSA of 4 to 20 µg/L were total PSA,
the proportion of free PSA, prostate volume,
and DRE findings, whereas age and a fam-
ily history of prostate cancer did not pro-
vide diagnostic information. The indepen-
dent variables were used to establish algo-
rithms for calculation of the probability of
detecting prostate cancer at biopsy. These
algorithms showed that the probability var-
ied greatly at a fixed level of serum PSA.
The overall probability of prostate cancer
for a man with a serum PSA of 4 µg/L was
about 0.18, but it varied between 0.02 and
0.69. This was mainly explained by varia-
tion in the proportion of free PSA but also
by prostate volume and DRE findings. This
finding demonstrates that combinations of
many variables can reduce the frequency of
false positive PSA results more efficiently
than the proportion of free PSA. Among
men with a serum PSA of 4–10 µg/L a neu-
ral network model, MLP, was shown to re-
duce false positive PSA results more effec-
tively than logistic regression. Using cut-
offs so that 95% of the cancer cases could
be detected 33%, 24%, and 19% of the false
positive PSA results could be eliminated,
respectively, with the MLP model, logistic
regression model, and the proportion of free
PSA.
The diagnostic models used in the present
investigation indicate that prostate volume
can predict negative biopsies simultaneously
with the proportion of free PSA. Predict-
able negative biopsies should be avoided
because they cause unnecessary expenses and
anxiety. Prostate volume cannot form the
basis for a biopsy decision if most urologists
always perform prostate biopsies when they
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measure prostate volume by TRUS. The
diagnostic algorithms developed in this
study can be made available on the internet
or in a pocket calculator or incorporated in
the software of the TRUS device. Thus, the
probability of detecting prostate cancer can
be obtained immediately when prostate vol-
ume has been measured and the biopsy de-
cision can be made bed-side. Furthermore,
in screening programs paramedical person-
nel can be trained to perform TRUS and
DRE (Schröder, et al., 1998).
8.6 Future prospects of early detection
of prostate cancer
Most screening programs use serum PSA
with a cutoff of 4 µg/L as a primary screen-
ing test to select men who should have a
prostate biopsy because of an increased risk
of prostate cancer. In some screening stud-
ies DRE or the proportion of free PSA has
been introduced as a second screening test
to identify subjects with increased prostate
cancer risk among men with a serum PSA
of 2.6 to 4 µg/L (Catalona, et al., 1997,
Määttänen, et al., 1999). The primary test
by which the whole population is screened
should be reasonably inexpensive for the
society and highly acceptable for the
screened subjects. This is true for PSA but
not for DRE or TRUS. Additional serum
markers can easily be determined from the
initial serum sample without bothering the
patient and thus serum markers are well
suited to increase the diagnostic accuracy
in the large group of men with a serum PSA
below 4 µg/L. The prevalence of prostate
cancer among men with a serum PSA be-
low 2 µg/L is very low (Schröder, et al.,
1998), and use of additional tests to iden-
tify high-risk cases among these is prob-
ably not worthwhile, especially if the screen-
ing is continuous.
A possible future model for improving
the accuracy of prostate cancer screening
could be measuring free PSA, PSA-API,
PSA-A2M and hK2 in serum from all men
with a PSA above 2 µg/L. Other serum vari-
ables could also be measured if found to be
useful. Men with a serum PSA below 2 µg/
L could be spared further investigations but
would have a new PSA test within 2–4
years. All serum markers and anamnestic
variables (age and family history if found
to be useful) would be used in a diagnostic
algorithm to identify patients who need a
clinical investigation including DRE and
TRUS. The clinical findings would be used
together with all other available important
variables in a second diagnostic algorithm
to identify patients who should have a pros-
tate biopsy. If indicated, this could be per-
formed immediately after the clinical in-
vestigation. This model for prostate cancer
screening would lead to performing biopsy
on many men with a serum PSA below 4
µg/L but avoiding it on a number of men
with a serum PSA higher than 4 µg/L. The
biopsy decision would be based on a pros-
tate cancer probability calculated on the
basis of all important variables available.
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9  Summary and conclusions
Prostate cancer is the most common cancer
among men in the industrialized world, and
it is the second most common cause of can-
cer death in men. Serum PSA is being used
for early detection of prostate cancer in popu-
lation screening but its utility is hampered
by a high frequency of false positive test re-
sults. The aim of the present investigation
was to develop and validate methods for re-
ducing the number of false positive PSA
results. The subjects studied were men with
a serum PSA of 4 µg/L or higher in the Finn-
ish prostate cancer screening trial.
Among men with a concentration of se-
rum PSA of 4 µg/L or higher, serum levels
of IGF-I were not significantly different be-
tween subjects with cancer and those with-
out. When adjusting for serum IGFBP-3,
serum IGF-I showed a negative association
with prostate cancer risk (OR 0.50, CI
0.26–0.97 for the highest vs. the lowest
quartile of IGF-I concentrations). Serum
IGF-I correlated positively with prostate
volume, and when also adjusting for pros-
tate volume the negative association be-
tween serum IGF-I and prostate cancer risk
was no longer statistically significant. In
ROC analysis the AUC of serum IGF-I was
0.55, indicating that it had no diagnostic
value.
A new assay for serum PSA-API was de-
veloped. By subtraction of the nonspecific
background signal the detection limit of the
assay could be lowered. The diagnostic in-
formation of serum PSA-API and the pro-
portion of free PSA were combined using
logistic regression analysis. Among men
with a serum PSA of 4–10 µg/L this com-
bination gave higher specificity (41% vs.
26%) at 95% sensitivity than the propor-
tion of free PSA (p<0.001).
The probability of detecting prostate
cancer in men with a serum PSA of 4–20
µg/L was estimated by logistic regression
analysis. Among those with a serum PSA
of 4 µg/L the overall probability was 0.18
but depending on the proportion of free
PSA, DRE findings and prostate volume
the probability varied between 0.02 and
0.69. An increase in serum total PSA from
4 to 10 µg/L increased the probability less
than a decrease in the proportion of free PSA
of 10 percent units.
Diagnostic models were constructed to
predict biopsy outcome among men with a
serum PSA of 4–10 µg/L using an artificial
neural network (MLP) and logistic regres-
sion. Serum PSA, the proportion of free
PSA, DRE findings and prostate volume
were found to be important diagnostic vari-
ables. At 95% sensitivity the MLP model
reduced the frequency of false positive PSA
results more effectively than the logistic
regression model or the proportion of free
PSA (33%, 24%, and 19%, respectively,
p<0.001).
In conclusion, serum IGF-I was not a use-
ful marker for prostate cancer among men
with elevated serum PSA. Use of PSA-API
in combination with the proportion of free
PSA provided higher diagnostic accuracy
than the proportion of free PSA alone. The
probability of detecting prostate cancer cal-
culated by logistic regression or MLP elimi-
nated false positive PSA results more accu-
rately than the proportion of free PSA.
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